Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrđan Verstovšek, H. Kantarjian, Murat O. Arcasoy et al.|Haematologica|2013Cited by 162